Trial · NCT07884903
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
NCT07884903, Not yet recruiting, Shanxi Bethune Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks. Trials, record NCT07884903. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884903
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
- NCT number
- NCT07884903
- Status
- Not yet recruiting
- Enrollment
- 25,974 participants, estimated
- Lead sponsor
- Shanxi Bethune Hospital
- Conditions
Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD), Cardiovascular Diseases, Sleep Apnea, Obstructives, Polycystic Ovary Syndrome, Hyperuricemia, Dyslipidemias
- Interventions
- No intervention; observational assessment only
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Type 2 Diabetes Mellitus | 3 years | 3-year incidence of new-onset type 2 diabetes mellitus diagnosed according to ADA criteria (fasting glucose ≥7.0 mmol/L, HbA1c ≥6.5%, or 2h OGTT ≥11.1 mmol/L) |
| Primary | Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 3 years | 3-year incidence of new-onset MASLD diagnosed by abdominal ultrasound and/or FibroScan with hepatic steatosis, excluding other causes of liver disease |
| Primary | Incidence of Hypertension | 3 years | 3-year incidence of new-onset hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg on at least 2 occasions, or initiation of antihypertensive medication) |
| Primary | Incidence of Atherosclerotic Cardiovascular Disease (ASCVD) | 3 years | 3-year incidence of ASCVD events including coronary heart disease, cerebral infarction, transient ischemic attack (TIA), and peripheral artery disease, confirmed by clinical diagnosis and imaging |
| Secondary | Incidence of Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) | 3 years | Diagnosed by polysomnography with AHI ≥5 events/hour |
| Secondary | Incidence of Polycystic Ovary Syndrome (PCOS) | 3 years | Diagnosed by Rotterdam criteria in women of reproductive age |
| Secondary | Incidence of Osteoarticular Disease | 3 years | New-onset lumbar/knee/hip joint disease confirmed by imaging |
| Secondary | Incidence of Hyperuricemia | 3 years | Serum uric acid \>420 μmol/L (men) or \>360 μmol/L (women) |
| Secondary | Incidence of Dyslipidemia | 3 years | New-onset abnormal lipid profile requiring treatment per guidelines |
| Secondary | Incidence of Microalbuminuria | 3 years | Urine albumin-to-creatinine ratio ≥30 mg/g on 2 occasions |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884903
GET https://conductscience.org/api/trials/v1/NCT07884903/registered